Nilotinib (TASIGNA CAP) Tablet

TASIGNA Capsule contains Nilotinib in strengths of 150mg and 200mg, serving as a medication primarily prescribed for the treatment of chronic myeloid leukemia (CML), a type of blood cancer characterized by the overproduction of white blood cells.

Key Features:

• Chronic Myeloid Leukemia (CML) Treatment: TASIGNA Capsule is indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults.
• Nilotinib Mechanism of Action: Nilotinib, the active ingredient in TASIGNA, is a tyrosine kinase inhibitor that targets the BCR-ABL protein, a fusion protein produced by the Philadelphia chromosome mutation that drives the abnormal proliferation of leukemic cells in CML.
• Multiple Strengths: Available in two strengths (150mg and 200mg), allowing for individualized dosing based on factors such as disease stage, patient’s response to treatment, and tolerability.
• Chronic Phase CML: TASIGNA is typically used as first-line therapy for newly diagnosed chronic phase CML, offering high rates of molecular response and improved long-term outcomes compared to older therapies.
• Accelerated Phase CML: In patients with accelerated phase CML or those who have become resistant or intolerant to other tyrosine kinase inhibitors, TASIGNA may be used as salvage therapy to help control disease progression.
• Fixed-Dose Capsule: TASIGNA Capsule contains a fixed dose of Nilotinib (150mg or 200mg) in each capsule, simplifying dosing and ensuring consistent medication delivery.
• Oral Administration: Administered orally, usually twice daily on an empty stomach, TASIGNA Capsule offers convenient dosing for patients with CML, allowing them to take their medication at home.
• Clinical Efficacy: Clinical trials have demonstrated the efficacy of Nilotinib in achieving and maintaining cytogenetic and molecular responses, as well as prolonging overall survival in patients with CML.
• Potential Adverse Effects: Common side effects of TASIGNA may include nausea, diarrhea, fatigue, rash, and elevated liver enzymes. Patients should be monitored closely for adverse reactions and managed accordingly.
• Individualized Treatment Approach: The selection of TASIGNA as a treatment option for CML should be based on factors such as disease phase, prior treatment history, presence of genetic mutations, and patient’s overall health status.